Alnylam Pharmaceuticals, Inc.
ALNY · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $1,249 | $774 | $594 | $593 |
| % Growth | 61.4% | 30.2% | 0.2% | – |
| Cost of Goods Sold | $197 | $143 | $71 | $103 |
| Gross Profit | $1,052 | $631 | $523 | $490 |
| % Margin | 84.2% | 81.5% | 88% | 82.7% |
| R&D Expenses | $359 | $324 | $265 | $300 |
| G&A Expenses | $322 | $323 | $240 | $295 |
| SG&A Expenses | $322 | $323 | $240 | $295 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $3 | $0 | $0 | $0 |
| Operating Expenses | $684 | $647 | $505 | $596 |
| Operating Income | $368 | -$16 | $18 | -$105 |
| % Margin | 29.5% | -2.1% | 3% | -17.7% |
| Other Income/Exp. Net | -$129 | -$19 | -$60 | -$89 |
| Pre-Tax Income | $239 | -$35 | -$42 | -$194 |
| Tax Expense | -$12 | $31 | $16 | -$110 |
| Net Income | $251 | -$66 | -$57 | -$84 |
| % Margin | 20.1% | -8.6% | -9.7% | -14.1% |
| EPS | 1.91 | -0.51 | -0.44 | -0.65 |
| % Growth | 474.5% | -15.9% | 32.3% | – |
| EPS Diluted | 1.84 | -0.51 | -0.44 | -0.65 |
| Weighted Avg Shares Out | 131 | 130 | 130 | 129 |
| Weighted Avg Shares Out Dil | 137 | 130 | 130 | 129 |
| Supplemental Information | – | – | – | – |
| Interest Income | $29 | $27 | $29 | $31 |
| Interest Expense | $44 | $40 | $39 | $39 |
| Depreciation & Amortization | $14 | $14 | $14 | $14 |
| EBITDA | $297 | $19 | $11 | -$141 |
| % Margin | 23.8% | 2.4% | 1.9% | -23.8% |